September, 2025
BUSINESS WIRE
Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
Read MoreSeptember, 2025
BUSINESS WIRE
Corstasis Therapeutics Strenghtens Leadership Team with the Appointment of Dr. Amin Medjamia as VP of Medical Affairs
Read MoreSeptember, 2025
BUSINESS WIRE
Corstasis Therapeutics Announces Allowance of a New Patent and Development Updates for Subcutaneous Programs RSQ-786 and RSQ-789
Read MoreSeptember, 2025
Orange County Business Journal
Corstasis Develops Nasal Spray for Congestive Heart Failure
Read MoreMarch, 2025
Yahoo Finance
Corstasis Therapeutics Inc. Announces FDA Acceptance of New Drug Application for Bumetanide Nasal Spray
Read MoreNovember, 2024
Yahoo Finance
Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024
Read MoreNovember, 2024
Cardiovascular Research Foundation
Nasal Bumetanide Safe, Effective in Healthy Adults
Read MoreNovember, 2024
American College of Cardiology
RSQ-777-02: New Nasal Spray Form of Bumetanide as Effective as Oral and IV Forms in Patients Without HF or HF Risk
Read MoreNovember, 2024
American Heart Association
Nasal spray version of common diuretic has potential to help treat heart failure
Read MoreJune, 2023
Medium